Net Assets per Single Share: OnKure Therapeutics, Inc. (OKUR)

Graphic logo of OnKure Therapeutics Inc (OKUR)

The development of OnKure Therapeutics Inc (OKUR) is independent of market cycles, as its success is based on drug trials. However, the absence of commercial revenue creates a financial vacuum. The net book value per share visualizes capital strength, where 4.28 shows the level of this metric. Business growth is constrained by strict FDA regulations and highly complex patent protection within the oncogene sector.

OKUR (OnKure) Accounting Value per Share history from 10/08/2024 to 10/30/2026

Financial and market metric breakdowns for OnKure Therapeutics, Inc. (OKUR)

- share price and expert price forecast:
Stock Quotes OnKure|OKUR - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value OnKure Therapeutics Inc|OKUR - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share OnKure Therapeutics|OKUR - Company Net Assets|Market Capitalization to Book Value Ratio onkuretherapeutics.com|OKUR - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Equity OnKure Therapeutics Inc|OKUR - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital OnKure|OKUR - Company Total Debt|Debts to Book Capitalization OnKure Therapeutics Inc|OKUR - Long-Term Debt|Company Short-Term Debt OnKure Therapeutics|Quick Liquidity Indicator onkuretherapeutics.com
- net income and valuation multiples indicators:
OKUR - Final Profit
Initial company analysis:onkuretherapeutics.com (OKUR)
Mass-produced product of OnKure Therapeutics, Inc.

Institutional capital assesses the attractiveness of OnKure Therapeutics Inc (OKUR) through the lens of investment security amid high binary risks associated with early-stage oncology drug development. By analyzing the current book value per share, investors can identify the remaining equity after all liabilities are settled, allowing them to determine the real value of their ownership stake and evaluate the biotech startup's resilience to potential liquidity shortages.

Main competitors

ONC: Accounting Value per Share|HALO - Book Value per Share|Revolution Medicines (RVMD) - Net Assets per Single Share|ascentage.com - Accounting Value of a Share|CGON (CG Oncology) - Book Value per Share|Accounting Value per Share UroGen Pharma Ltd (URGN)|Book Value per Share BCAX|Book Value per Share Personalis Genomics (PSNL)|Net Assets per Single Share Erasca, Inc. ERAS|DCTH: Equity per Share|Y-mAbs Therapeutics, Inc. - Book Value per Share|Aura Biosciences Inc (AURA) - Accounting Value per Share|CADL: Book Value per Share|Net Asset Value per Share Accuray, Inc. (ARAY)|Net Assets per Single Share SELLAS Life Sciences Group, Inc.|ACTU: Accounting Value of a Share|Accounting Value per Share CTOR (Citius Oncology)|HURA (tuhurabio.com) - Accounting Value of a Share|Book Value per Share TARA (Protara)|FATE - Accounting Value per Share|WHWK: Accounting Value per Share|TCRX - Book Value per Share|championsoncology.com (CSBR) - Net Assets per Single Share|XBiotech - Accounting Value of a Share|CVM (CEL-SCI Corp.) - Book Value per Share|Net Asset Value per Share OS Therapies, Inc. OSTX|Net Assets per Single Share Radiopharm Theranostics Limited (RADX)|ARTV - Net Asset Value per Share|Net Assets per Single Share Adlai Nortye ANL|VERU: Equity per Share|TPST - Net Assets per Single Share|XLO - Book Value per Share|RENB (renovarobio.com) - Accounting Value per Share|Mural Oncology (MURA) - Book Value per Share|Net Assets per Single Share Kairos Pharma Limited|GDTC: Accounting Value of a Share|Book Value per Share CRIS|APLM - Net Asset Value per Share|Tharimmune, Inc. - Accounting Value per Share|Accounting Value of a Share ADVB|GNPX: Accounting Value per Share|Calidi Biotherapeutics - Book Price of a Share|SBFM: Book Value per Share|Xenetic Biosciences, Inc. - Accounting Value of a Share|SLRX (Salarius Pharmaceuticals) - Book Value per Share|Net Asset Value per Share purple-biotech.com PPBT|Net Assets per Single Share American Oncology Network (AONC)|BGNE (BeiGene Ltd.) - Accounting Value of a Share|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|Book Value per Share elevationoncology.com ELEV|ICAD - Net Assets per Single Share|Share Book Value IKNA|NTBL: Book Value per Share|Net Asset Value per Share Viracta Therapeutics, Inc. (VIRX)|Accounting Value per Share MOR|Book Value per Share NAYA Biosciences Corp|Accounting Value per Share AAPGV (Ascentage Pharma Group)